Submissions from biorxiv.org

• A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

  (biorxiv.org)

  Published on 16th Feb 2021
• In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2

  (biorxiv.org)

  Published on 12th Feb 2021
• Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

  (biorxiv.org)

  Published on 12th Feb 2021
• Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain

  (biorxiv.org)

  Published on 12th Feb 2021
• Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

  (biorxiv.org)

  Published on 12th Feb 2021
• SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination

  (biorxiv.org)

  Published on 12th Feb 2021
• Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

  (biorxiv.org)

  Published on 9th Feb 2021
• mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

  (biorxiv.org)

  Published on 24th Jan 2021
• The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: A Free energy of perturbation study

  (biorxiv.org)

  Published on 14th Jan 2021
• Emergence and Evolution of a Prevalent New SARS-CoV-2 Variant in the United States

  (biorxiv.org)

  Published on 14th Jan 2021
• Cryo-EM Structure of the N501Y SARS-CoV-2 Spike Protein in Complex with a Potent Neutralizing Antibody

  (biorxiv.org)

  Published on 14th Jan 2021
• SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor. (Is this the first structure of these Spike single amino acid substitutions in combo? Specifically N501Y and E484K. All I've seen prior are predictions)

  (biorxiv.org)

  Published on 14th Jan 2021
• The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation

  (biorxiv.org)

  Published on 3rd Jan 2021
• MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease

  (biorxiv.org)

  Published on 3rd Jan 2021
• Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccine

  (biorxiv.org)

  Published on 20th Dec 2020
• Glycyrrhizin effectively neutralizes SARS-CoV-2 in vitro by inhibiting the viral main protease

  (biorxiv.org)

  Published on 20th Dec 2020
• Molnupiravir (EIDD-2801) inhibits SARS-CoV2 replication in Syrian hamsters model

  (biorxiv.org)

  Published on 13th Dec 2020
• SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray

  (biorxiv.org)

  Published on 13th Dec 2020
• A single dose, BCG-adjuvanted SARS-CoV-2 vaccine induces Th1-polarized immunity and high-titre neutralizing antibodies in mice

  (biorxiv.org)

  Published on 13th Dec 2020
• Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro

  (biorxiv.org)

  Published on 7th Dec 2020
• First-described recently discovered non-toxic vegetal-derived furocoumarin preclinical efficacy against SARS-CoV-2: a promising antiviral herbal drug.

  (biorxiv.org)

  Published on 7th Dec 2020
• Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures

  (biorxiv.org)

  Published on 7th Dec 2020
• Decontamination of Common Healthcare Facility Surfaces Contaminated with SARS-CoV-2 using Peracetic Acid Dry Fogging

  (biorxiv.org)

  Published on 7th Dec 2020
• An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19

  (biorxiv.org)

  Published on 7th Dec 2020
• The N-glycosylation sites and Glycan-binding ability of S-protein in SARS-CoV-2 Coronavirus

  (biorxiv.org)

  Published on 2nd Dec 2020
• Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

  (biorxiv.org)

  Published on 2nd Dec 2020
• Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro

  (biorxiv.org)

  Published on 29th Nov 2020
• Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

  (biorxiv.org)

  Published on 29th Nov 2020
• A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL)

  (biorxiv.org)

  Published on 29th Nov 2020
• SARS-CoV-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan

  (biorxiv.org)

  Published on 23rd Nov 2020
• Anti-COVID-19 efficacy of ivermectin in the golden hamster

  (biorxiv.org)

  Published on 23rd Nov 2020
• Resistance of endothelial cells to SARS-CoV-2 infection in vitro

  (biorxiv.org)

  Published on 10th Nov 2020
• Identification of a unique TCR repertoire, consistent with a superantigen selection process in Children with Multi-system Inflammatory Syndrome

  (biorxiv.org)

  Published on 10th Nov 2020
• Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

  (biorxiv.org)

  Published on 8th Nov 2020
• Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

  (biorxiv.org)

  Published on 8th Nov 2020
• Variability of Accessory Proteins Rules the SARS-CoV-2 Pathogenicity

  (biorxiv.org)

  Published on 8th Nov 2020
• An evolutionary portrait of the progenitor SARS-CoV-2 and its dominant offshoots in COVID-19 pandemic

  (biorxiv.org)

  Published on 8th Nov 2020
• Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection

  (biorxiv.org)

  Published on 8th Nov 2020
• SARS-CoV-2 spike D614G variant confers enhanced replication and transmissibility

  (biorxiv.org)

  Published on 1st Nov 2020
• The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

  (biorxiv.org)

  Published on 27th Oct 2020
• Cone-shaped HIV-1 capsids are transported through intact nuclear pores: Correlative-live cell electron microscopy (CLEM) findings suggest dilation of NPCs in infected cells allows for passage intact cores without significant remodeling.

  (biorxiv.org)

  Published on 27th Oct 2020
• Comparison of the in vitro-efficacy of different mouthwash solutions targeting SARS-CoV-2 based on the European Standard EN 14476

  (biorxiv.org)

  Published on 27th Oct 2020
• A DNA-origami nuclear pore mimic reveals nuclear entry mechanisms of HIV-1 capsid: ssDNA fashioned to imitate structural constraints of the NPC provides insight into recent research unprecedentedly suggesting the HIV-1 core uncoats within the nucleus.

  (biorxiv.org)

  Published on 15th Oct 2020
• Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice

  (biorxiv.org)

  Published on 12th Oct 2020
• The human brain vasculature shows a distinct expression pattern of SARS-CoV-2 entry factors

  (biorxiv.org)

  Published on 12th Oct 2020
• Extremely potent human monoclonal antibodies from convalescent Covid-19 patients

  (biorxiv.org)

  Published on 8th Oct 2020
• GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition

  (biorxiv.org)

  Published on 7th Oct 2020
• Transcriptional differences for COVID-19 Disease Map genes between males and females indicate a different basal immunophenotype relevant to the disease

  (biorxiv.org)

  Published on 2nd Oct 2020
• SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro

  (biorxiv.org)

  Published on 2nd Oct 2020
• LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

  (biorxiv.org)

  Published on 2nd Oct 2020
• S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

  (biorxiv.org)

  Published on 25th Sep 2020
• Respiratory disease in cats associated with human-to-cat transmission of SARS-CoV-2 in the UK

  (biorxiv.org)

  Published on 24th Sep 2020
• The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro

  (biorxiv.org)

  Published on 21st Sep 2020
• Topography, spike dynamics and nanomechanics of individual native SARS-CoV-2 virions

  (biorxiv.org)

  Published on 21st Sep 2020
• Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model

  (biorxiv.org)

  Published on 18th Sep 2020
• Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2.

  (biorxiv.org)

  Published on 15th Sep 2020
• No evidence of coronaviruses or other potentially zoonotic viruses in Sunda pangolins (Manis javanica) entering the wildlife trade via Malaysia

  (biorxiv.org)

  Published on 15th Sep 2020
• Ketogenesis restrains aging-induced exacerbation of COVID in a mouse model

  (biorxiv.org)

  Published on 13th Sep 2020
• Human IFITM3 restricts Chikungunya virus and Mayaro virus infection and is susceptible to virus-mediated counteraction

  (biorxiv.org)

  Published on 13th Sep 2020
• A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

  (biorxiv.org)

  Published on 9th Sep 2020
• Long-term survival of salmon-attached SARS-CoV-2 at 4 degree as a potential source of transmission in seafood markets

  (biorxiv.org)

  Published on 7th Sep 2020
• Versatile, Multivalent Nanobody Cocktails for Highly Efficient SARS-CoV-2 Neutralization

  (biorxiv.org)

  Published on 28th Aug 2020
• Susceptibility of rabbits to SARS-CoV-2

  (biorxiv.org)

  Published on 28th Aug 2020
• An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2

  (biorxiv.org)

  Published on 21st Aug 2020
• SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways

  (biorxiv.org)

  Published on 20th Aug 2020
• Equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers

  (biorxiv.org)

  Published on 20th Aug 2020
• Peptide Antidotes to SARS-CoV-2 (COVID-19)

  (biorxiv.org)

  Published on 18th Aug 2020
• A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model

  (biorxiv.org)

  Published on 17th Aug 2020
• An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation

  (biorxiv.org)

  Published on 11th Aug 2020
• Peptide Antidotes to SARS-CoV-2 (COVID-19)

  (biorxiv.org)

  Published on 9th Aug 2020
• De novo design of ACE2 protein decoys to neutralize SARS-CoV-2

  (biorxiv.org)

  Published on 6th Aug 2020
• Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

  (biorxiv.org)

  Published on 6th Aug 2020
• Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19

  (biorxiv.org)

  Published on 6th Aug 2020
• Host metabolic reprogramming in response to SARS-Cov-2 infection

  (biorxiv.org)

  Published on 6th Aug 2020
• Infection of human lymphomononuclear cells by SARS-CoV-2

  (biorxiv.org)

  Published on 6th Aug 2020
• Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection

  (biorxiv.org)

  Published on 6th Aug 2020
• Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

  (biorxiv.org)

  Published on 3rd Aug 2020
• CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation

  (biorxiv.org)

  Published on 31st Jul 2020
• Respiratory bacteria stabilize and promote airborne transmission of influenza A virus

  (biorxiv.org)

  Published on 29th Jul 2020
• Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans

  (biorxiv.org)

  Published on 24th Jul 2020
• Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

  (biorxiv.org)

  Published on 23rd Jul 2020
• Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy

  (biorxiv.org)

  Published on 22nd Jul 2020
• SARS-CoV-2 Spike protein hijacks VEGF-A/Neuropilin-1 receptor signaling to induce analgesia

  (biorxiv.org)

  Published on 19th Jul 2020
• Interplay of Monocytes and T Lymphocytes in COVID-19 Severity

  (biorxiv.org)

  Published on 19th Jul 2020
• A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection

  (biorxiv.org)

  Published on 17th Jul 2020
• Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro

  (biorxiv.org)

  Published on 13th Jul 2020
• Genomic variations in SARS-CoV-2 genomes from Gujarat: Underlying role of variants in disease epidemiology

  (biorxiv.org)

  Published on 12th Jul 2020
• ACE2-expressing endothelial cells in aging mouse brain

  (biorxiv.org)

  Published on 12th Jul 2020
• Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men

  (biorxiv.org)

  Published on 9th Jul 2020
• Single source of pangolin CoVs with a near identical Spike RBD to SARS-CoV-2

  (biorxiv.org)

  Published on 8th Jul 2020
• The major genetic risk factor for severe COVID-19 is inherited from Neandertals

  (biorxiv.org)

  Published on 5th Jul 2020
• Alpha-1 antitrypsin inhibits SARS-CoV-2 infection

  (biorxiv.org)

  Published on 3rd Jul 2020
• Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2

  (biorxiv.org)

  Published on 2nd Jul 2020
• Detection of Viral RNA Fragments in Human iPSC-Cardiomyocytes following Treatment with Extracellular Vesicles from SARS-CoV-2 Coding-Sequence-Overexpressing Lung Epithelial Cells

  (biorxiv.org)

  Published on 2nd Jul 2020
• A simple, safe and sensitive method for SARS-CoV-2 inactivation and RNA extraction for RT-qPCR

  (biorxiv.org)

  Published on 2nd Jul 2020
• If the link missed：Could inflammatory skin disorders with barrier dysfunction increase the risk of COVID-19?

  (biorxiv.org)

  Published on 2nd Jul 2020
• SARS-CoV-2 reactive T cells in uninfected individuals are likely expanded by beta-coronaviruses

  (biorxiv.org)

  Published on 2nd Jul 2020
• Citizen Scientists Create an Exascale Computer to Combat COVID-19

  (biorxiv.org)

  Published on 1st Jul 2020
• A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

  (biorxiv.org)

  Published on 1st Jul 2020
• SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

  (biorxiv.org)

  Published on 1st Jul 2020
• An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19

  (biorxiv.org)

  Published on 1st Jul 2020